Last reviewed · How we verify
Omega-3 fatty acid ethylester90
Omega-3 fatty acid ethylester90 is a Omega-3 fatty acid derivative Small molecule drug developed by Kuhnil Pharmaceutical Co., Ltd.. It is currently in Phase 3 development for Hypertriglyceridemia, Cardiovascular disease prevention. Also known as: Omacor®.
Omega-3 fatty acid ethylester reduces triglycerides and modulates lipid metabolism by increasing fatty acid oxidation and reducing hepatic triglyceride synthesis.
Omega-3 fatty acid ethylester reduces triglycerides and modulates lipid metabolism by increasing fatty acid oxidation and reducing hepatic triglyceride synthesis. Used for Hypertriglyceridemia, Cardiovascular disease prevention.
At a glance
| Generic name | Omega-3 fatty acid ethylester90 |
|---|---|
| Also known as | Omacor® |
| Sponsor | Kuhnil Pharmaceutical Co., Ltd. |
| Drug class | Omega-3 fatty acid derivative |
| Target | PPAR, GPR120 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Omega-3 fatty acids (EPA and DHA) work by activating peroxisome proliferator-activated receptors (PPARs) and G-protein coupled receptor 120 (GPR120), which enhance fatty acid oxidation in mitochondria and reduce the production of triglyceride-rich lipoproteins in the liver. This leads to decreased circulating triglyceride levels and improved lipid profiles, with potential anti-inflammatory and cardioprotective effects.
Approved indications
- Hypertriglyceridemia
- Cardiovascular disease prevention
Common side effects
- Gastrointestinal upset
- Fishy aftertaste
- Bleeding tendency
- Nausea
Key clinical trials
- Effect of Omega-3 Fatty Acid on Vitamin D Activation (PHASE4)
- Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omega-3 fatty acid ethylester90 CI brief — competitive landscape report
- Omega-3 fatty acid ethylester90 updates RSS · CI watch RSS
- Kuhnil Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Omega-3 fatty acid ethylester90
What is Omega-3 fatty acid ethylester90?
How does Omega-3 fatty acid ethylester90 work?
What is Omega-3 fatty acid ethylester90 used for?
Who makes Omega-3 fatty acid ethylester90?
Is Omega-3 fatty acid ethylester90 also known as anything else?
What drug class is Omega-3 fatty acid ethylester90 in?
What development phase is Omega-3 fatty acid ethylester90 in?
What are the side effects of Omega-3 fatty acid ethylester90?
What does Omega-3 fatty acid ethylester90 target?
Related
- Drug class: All Omega-3 fatty acid derivative drugs
- Target: All drugs targeting PPAR, GPR120
- Manufacturer: Kuhnil Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertriglyceridemia
- Indication: Drugs for Cardiovascular disease prevention
- Also known as: Omacor®
- Compare: Omega-3 fatty acid ethylester90 vs similar drugs
- Pricing: Omega-3 fatty acid ethylester90 cost, discount & access